ArticleJCO precision oncology2021

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer.

Caroline E McCoach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.